[go: up one dir, main page]

YU56103A - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrochloride dihydrate

Info

Publication number
YU56103A
YU56103A YU56103A YUP56103A YU56103A YU 56103 A YU56103 A YU 56103A YU 56103 A YU56103 A YU 56103A YU P56103 A YUP56103 A YU P56103A YU 56103 A YU56103 A YU 56103A
Authority
YU
Yugoslavia
Prior art keywords
hydrochloride dihydrate
improved process
ondansetron hydrochloride
preparing pure
pure ondansetron
Prior art date
Application number
YU56103A
Other languages
Serbo-Croatian (sh)
Inventor
Ramy Lidor Hadas
Eliezer Bachar
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of YU56103A publication Critical patent/YU56103A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

An improved method for preparing dimethylamino-methyl-carbazolone and ondansetron base. A recrystallization process for preparing pure ondansetron hydrochloride dihydrate with a purity of at least 99.0% is also disclosed.
YU56103A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate YU56103A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11

Publications (1)

Publication Number Publication Date
YU56103A true YU56103A (en) 2006-05-25

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
YU56103A YU56103A (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Country Status (21)

Country Link
EP (1) EP1355881A4 (en)
JP (1) JP2004526692A (en)
KR (3) KR20070054749A (en)
CN (2) CN101045704A (en)
AU (1) AU2002236753B2 (en)
CA (1) CA2433720A1 (en)
CZ (1) CZ20032090A3 (en)
DE (1) DE02703115T1 (en)
ES (1) ES2219201T1 (en)
HR (1) HRP20030631A2 (en)
HU (1) HUP0400767A2 (en)
IL (1) IL156835A0 (en)
IS (1) IS6869A (en)
MX (1) MXPA03006215A (en)
NO (1) NO20033147L (en)
PL (1) PL368837A1 (en)
SK (1) SK9892003A3 (en)
TR (1) TR200401460T3 (en)
WO (1) WO2002055492A2 (en)
YU (1) YU56103A (en)
ZA (1) ZA200305338B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60314400T2 (en) 2002-04-29 2008-02-07 Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL-1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (en) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronformer
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
WO2006046253A1 (en) * 2004-10-26 2006-05-04 Ipca Laboratories Limited A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
CA2426026A1 (en) * 2000-10-30 2002-05-10 Judith Aronhime Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Also Published As

Publication number Publication date
CA2433720A1 (en) 2002-07-18
PL368837A1 (en) 2005-04-04
IL156835A0 (en) 2004-02-08
ZA200305338B (en) 2004-07-12
SK9892003A3 (en) 2004-05-04
EP1355881A4 (en) 2004-03-31
CN1496350A (en) 2004-05-12
DE02703115T1 (en) 2004-10-21
KR20070054749A (en) 2007-05-29
MXPA03006215A (en) 2005-02-17
EP1355881A2 (en) 2003-10-29
HRP20030631A2 (en) 2005-06-30
NO20033147D0 (en) 2003-07-09
KR20030068583A (en) 2003-08-21
CN101045704A (en) 2007-10-03
ES2219201T1 (en) 2004-12-01
NO20033147L (en) 2003-09-02
HUP0400767A2 (en) 2004-07-28
WO2002055492A2 (en) 2002-07-18
JP2004526692A (en) 2004-09-02
WO2002055492A3 (en) 2003-02-13
IS6869A (en) 2003-07-08
CZ20032090A3 (en) 2004-08-18
TR200401460T3 (en) 2004-08-23
AU2002236753B2 (en) 2007-06-28
KR20060113792A (en) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2004011453A3 (en) Method for preparing 3-halo-4,5-dihydro-1h-pyrazoles
HU0101336D0 (en) Process for the preparation of perindopril and their pharmaceutically acceptable salts
WO2004052899A3 (en) Process for the production of 2'-branched nucleosides
MXPA02012795A (en) Carvedilol.
NZ536141A (en) Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
IL114894A0 (en) Endothelin antagonists
MY134083A (en) Crystalline clindamycin free base
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
AU2003293585A8 (en) Intermediate cefdinir salts
MXPA03004426A (en) Chemical process and new intermediates.
YU56103A (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
YU30203A (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
BG104243A (en) Method for the synthesis of quinoline derivatives
NO20062599L (en) Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
IL159304A (en) Process for the production of piperidine derivatives
MY130488A (en) Process for preparing 3,3',6,6'-tetraalkyl-2,2'-biphenols and 3,3',6,6'-tetraalkyl-5,5'-dihalo-2,2'-biphenols
AU2003240634A8 (en) Method for producing bicalutamide
MXPA03010943A (en) Process for preparing a thialzole ppar-ligand and polymorphs thereof.
MXPA03006057A (en) Process for preparing (plusmn;) trans-4 -p-fluorophenyl -3-hydroxymethyl -1-methylpiperidine.
PL331330A1 (en) Method of obtaining derivatives of 3-pyroline-2-carboxylic acid
HU0201262D0 (en)
CZ20011915A3 (en) Process for preparing cyclene
YU71400A (en) Improved method for preparing pharmaceutically valuable norbenzomorphane derivatives
PL369244A1 (en) N-methyl-homocystines, use thereof and method for the production thereof